Why Liver Monitoring Matters with Bosentan
Bosentan (Tracleer), used for pulmonary arterial hypertension, carries a boxed warning for serious liver injury, including rare cases of liver failure and death. Liver function tests (LFTs) measuring ALT and AST are required before starting and regularly during treatment to detect hepatotoxicity early.[1][2]
Recommended Liver Check Schedule
- Before starting: Check ALT/AST within 3 days.
- Monthly for first 3 months: Test every month.
- Every 3 months thereafter: Continue indefinitely, or more often if doses change or abnormalities appear.
- If levels rise: 3x upper limit of normal (ULN) requires dose reduction or discontinuation; >8x ULN mandates stopping the drug.[1][3]
Guidelines from the FDA label and manufacturer emphasize no exceptions for routine monitoring—it's mandatory for all patients.[2]
What Happens If Liver Enzymes Elevate
Up to 11% of patients see ALT/AST >3x ULN, usually within the first year, often reversible with dose adjustment or stopping. Risk factors include higher doses (>125 mg twice daily), female sex, and underlying liver disease. Symptoms like nausea, fatigue, or jaundice warrant immediate testing.[1][3]
Who Might Need Extra Monitoring
Patients with baseline liver issues, HIV co-infection, or those on interacting drugs (e.g., statins, rifampin) face higher risks. Pregnancy testing is also required monthly due to teratogenicity, but liver checks remain separate.[2]
Bosentan vs. Similar Drugs
Compared to other endothelin receptor antagonists like ambrisentan (Letairis) or macitentan (Opsumit), bosentan has the strictest liver monitoring due to higher hepatotoxicity rates. Ambrisentan requires checks only if symptoms arise or at 3/6/12 months initially.[3]
[1]: FDA Label for Tracleer (bosentan)
[2]: Drugs.com - Bosentan Warnings
[3]: UpToDate - Bosentan Monitoring